# US 2024/0199651 A1 · Antibacterial compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199651 A1
- Document ID: US20240199651A1
- Status: Published application
- Kind: A1
- Application number: 18/550,342
- Filed: 2022-03-16
- Published: 2024-06-20
- Earliest claimed: 2021-03-17
- Assignees: Janssen Sciences Ireland Unlimited Company
- Applicants: Janssen Sciences Ireland Unlimited Company
- Inventors: Jérôme Émile Georges GUILLEMONT; Magali Madeleine Simone MOTTE; Dirk Antonie LAMPRECHT; José Manuel BARTOLOMÉ-NEBREDA
- Web page: https://patentgrep.com/patent/US20240199651A1

## CPC

- A61P 31/04: Antibacterial agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/06: for tuberculosis
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.

## Claims

### Claim 1

A compound of formula (I);
wherein:
A is a 5- or 6-membered ring, which is aromatic or non-aromatic, and optionally containing 1 or 2 heteroatoms that are nitrogen, sulfur or oxygen;
B is a 5-membered aromatic ring containing 1 or 2 nitrogen heteroatoms;
X1 is ═N— or ═C(R10a)—;
X1b is ═N— or ═C(R3)—.
X1c is ═C(R10a) or ═N—;
X1d is ═C(R10a) or ═N—, and wherein a maximum of two of X1, X1b, X1c and C1d are ═N—;
one of X2 and X3 in the D ring is ═N— and the other is ═N— or ═C(R10b)—;
L1 is a linker group;
L2 is an optional linker group;
R1 is one or more optional substituents independently that are halo, —R5a, —O—R5b, —C(═O)—R5c, —C(═O)—N(R6)(R7), —CN or —N(R6a)R6b; or any two R1 groups are taken together when attached to adjacent atoms of the A ring to form a 5- or 6-membered ring optionally containing one or two heteroatoms, and which ring is optionally substituted by one or two C1-3 alkyl substituents;
R2 is —C1-4 alkyl optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
R3 is a substituent that is H, F, —C1-3 alkyl or —O—C1-3 alkyl;
R4 is H, —R8a, —C(═O)—R8b, —SO2—R9 or Het1;
R5a and R5b independently are hydrogen or —C1-4 alkyl optionally substituted by one or more substituents that are halo, —O—CH3 or phenyl;
R5 is —C1-3 alkyl;
R6 and R7 are independently H or —C1-3 alkyl;
R6a and R6b independently are H, C1-6 alkyl or R6a and R6b are linked together to form a 3- to 6-membered ring;
R8a is —C1-4 alkyl, optionally substituted by one or more substituents that are halo, —OC1-3 alkyl, —CN or Het2;
R8b is hydrogen or —C1-3 alkyl optionally substituted by one or more fluoro atoms;
R9 is Het3, —N(R6c)R6d or —C1-4 alkyl optionally substituted by one or more substituents that are halo or —O—CH3;
R6c and R6d independently represent are H, C1-6 alkyl or R6c and R6d are linked together to form a 3- to 6-membered ring;
R10a and R10b independently represent are H, halo, C1-4 alkyl (optionally substituted by one or more substituent(s) that are fluoro, —CN, —R11a, —OR11b, —N(R11c)R11d, and/or —C(O)N(R11e)R11f or —O—C1-4 alkyl itself optionally substituted by one or more substituent(s) that are fluoro, —R11g, —OR11h or —N(R11i)R11j;
R11a, R11b, R11c, R11d, R11e, R11f, R11g, R11h, R11i and R11j independently are hydrogen or C1-3 alkyl optionally substituted by one or more fluoro atoms;
R12a and R12b independently represent are hydrogen or C1-3 alkyl; or R12a and R12b are linked together to form a 3- to 6-membered ring;
R12c and R12d independently are hydrogen or C1-3 alkyl; or R12c and R12d are linked together to form a 3- to 6-membered ring;
Het1, Het2 and Het3 independently are a 5- or 6-membered aromatic ring containing one or two heteroatoms, optionally substituted by one or more substituents that are halo or C1-3 alkyl optionally substituted by one or more fluoro atoms,
or a pharmaceutically-acceptable salt thereof.

### Claim 2

A compound of formula (I):
wherein:
A is a 5- or 6-membered ring, which is aromatic or non-aromatic, and optionally containing 1 or 2 heteroatoms that are nitrogen, sulfur or oxygen;
B is a 5-membered aromatic ring containing 1 or 2 nitrogen heteroatoms;
X1 is ═N— or ═C(R10a)—;
one of X2 and X3 is ═N— and the other is ═N— or ═C(R10b)—;
L1 is a linker group;
L2 is an optional linker group;
R1 is one or more optional substituents independently that are halo, —R5a, —O—R5b, —C(═O)—R5c, —C(═O)—N(R6)(R7), —CN or —N(R6a)R6b; or any two R1 groups are taken together when attached to adjacent atoms of the A ring to form a 5- or 6-membered ring optionally containing one or two heteroatoms, and which ring is optionally substituted by one or two C1-3 alkyl substituents;
R2 is —C1-4 alkyl optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
R3 is a substituent that is H, F, —C1-3 alkyl —O—C1-3 alkyl;
R4 is H, —R8a, —C(═O)—R8b, —SO2—R9 or Het1;
R5a and R5b independently are hydrogen or —C1-4 alkyl optionally substituted by one or more substituents that are halo, —O—CH3 or phenyl;
R5c is —C1-3 alkyl;
R6 and R7 are independently H or —C1-3 alkyl;
R6a and R6b independently are H, C1-6 alkyl or R6a and R6b are linked together to form a 3- to 6-membered ring;
R8a is —C1-4 alkyl, optionally substituted by one or more substituents that are halo, —OC1-3 alkyl, —CN or Het2;
R8b is hydrogen or —C1-3 alkyl optionally substituted by one or more fluoro atoms;
R9 is Het3, —N(R6c)R6d or —C1-4 alkyl optionally substituted by one or more substituents that are halo or —O—CH3;
R6c and R6d independently are H, C1-6 alkyl or R6c and R6d are linked together to form a 3- to 6-membered ring;
R10a and R10b independently are H, halo, C1-4 alkyl itself optionally substituted by one or more substituent(s) that are fluoro, —CN, —R11a, —OR11b, —N(R11c)R11d or —C(O)N(R11e)R11f or —O—C1-4 alkyl itself optionally substituted by one or more substituent(s) that are fluoro, —R11g, —OR11h or —N(R11i)R11j;
R11a, R11b, R11c, R11a, R11e, R11f, R11g, R11h, R11i and R11j independently are hydrogen or C1-3 alkyl optionally substituted by one or more fluoro atoms;
R12a and R12b independently are hydrogen or C1-3 alkyl; or R12a and R12b are linked together to form a 3- to 6-membered ring;
R12c and R12d independently are hydrogen or C1-3 alkyl; or R12c and R12d are linked together to form a 3- to 6-membered ring;
Het1, Het2 and Het3 independently are a 5- or 6-membered aromatic ring containing one or two heteroatoms, optionally substituted by one or more substituents that are halo or C1-3 alkyl (optionally substituted by one or more fluoro atoms,
or a pharmaceutically-acceptable salt thereof,

### Claim 3 (depends on 1)

The compound according to claim 1,
wherein ring A is as follows:

### Claim 4 (depends on 1)

The compound according to claim 1, wherein ring A and ring B may be represented are as follows:

### Claim 5 (depends on 1)

The compound according to claim 1, wherein ring C is as follows:

### Claim 6 (depends on 1)

The compound according to claim 1, wherein ring D is as follows:

### Claim 7 (depends on 1)

The compound according to claim 1, wherein L1 is a linker group that is —CH2—, —CH2—CH2—, or —C(R12a)(R12b)—, wherein R12a and R12b each independently are —CH3 or are linked together to form a 3-membered ring.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein L2 is a linker group that is a direct bond, —CH2—, or a 4- or 5- or 6-membered non-aromatic ring optionally containing one or two nitrogen atom(s).

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the compound of claim 1.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method treating a mycobacterial infection in a patient, comprising administering a therapeutically effective amount of the compound of claim 1 to the patient.

### Claim 14 (depends on 1)

A combination of (a) the compound of claim 1, and (b) one or more other anti-mycobacterial agent.

### Claim 15 (depends on 1)

A product containing (a) the compound of claim 1, and (b) one or more other anti-mycobacterial agent, as a combined preparation for simultaneous, separate or sequential use in treating a bacterial infection.

### Claim 16 (depends on 1)

A process for preparing the compound of formula (I) of claim 1, comprising (i) reacting a compound of formula (XXX):
with a compound of formula (XXXI):
(ii) coupling of a compound of formula (XXXII)
wherein R13 is suitable leaving group, with a compound of formula (XXXIII):
wherein R14 is a suitable leaving group.

### Claim 17 (depends on 1)

The compound according to claim 1, wherein:
(i) the C ring is phenyl, pyridyl, pyrimidinyl;
(ii) L1 is —C(R12a)(R12b)— or C2-4 alkylene optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
(iii) L1 is situated para or meta relative to L2;
(iv) L1 is attached to X1d or the carbon atom in between X1d and X1c;
(v) L2 is a direct bond, —O—, —OCH2—, —C(R12c)(R12d)— or C2-4 alkylene optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
(vi) L2 is a 4-, 5- or 6-membered aromatic or non-aromatic cyclic linker group, optionally containing one or two heteroatoms and optionally substituted by one or more substituents that are halo or C1-3 alkyl optionally substituted by one or more fluoro atoms;
(vii) L2 is a 4-, 5- or 6-membered aromatic or non-aromatic cyclic linker group, optionally containing one or two heteroatoms that are nitrogen, oxygen or sulfur and optionally substituted by one or more substituents that are halo or C1-3 alkyl optionally substituted by one or more fluoro atoms;
(viii) R5a and R5b independently are a linear, branched or cyclic alkyl;
(ix) R1 is one, two or three substituents;
(x) R1 is Cl or F;
(xi) R2 is C3-4 cycloalkyl;
(xii) R5a and R5b independently are linear, branched or cyclic alkyl;
(xiii) R5a and R5b independently are optionally substituted by one or more F;
(xiv) R9 is —C1-4 alkyl substituted by one or more F;
(xv) R10a and R10b independently are C1-4 alkyl substituted by one substituent;
(xvi) R10a and R10b independently are —O—C1-4 alkyl substituted by one substituent; and/or
(xvii) Het1, Het2 and Het3 independently are a 5- or 6-membered aromatic ring containing one or two heteroatoms that are nitrogen, oxygen or sulfur.

### Claim 18 (depends on 2)

The compound according to claim 2, wherein:
(i) L1 is —C(R12a)(R12b)— or C2-4 alkylene optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
(ii) L2 is a direct bond, —O—, —OCH2—, —C(R12c)(R12d)— or C2-4 alkylene optionally substituted by one or more substituents that are halo or —OC1-3 alkyl;
(iii) L2 is a 4-, 5- or 6-membered aromatic or non-aromatic cyclic linker group, optionally containing one or two heteroatoms and optionally substituted by one or more substituents that are halo or C1-3 alkyl that is itself optionally substituted by one or more fluoro atoms;
(iv) L2 is a 4-, 5- or 6-membered aromatic or non-aromatic cyclic linker group, containing one or two heteroatoms that are nitrogen, oxygen or sulfur;
(v) R1 is one, two or three substituents;
(vi) R1 is Cl or F;
(vii) R5a and R5b independently are —C1-4 alkyl substituted by one or more F;
(viii) R9 is —C1-4 alkyl substituted by one or more F;
(ix) R10a and R10b independently are C1-4 alkyl substituted by one substituent;
(x) R10a and R10b independently are —O—C1-4 alkyl substituted by one substituent;
and/or
(xi) Het1, Het2 and Het3 independently are a 5- or 6-membered aromatic ring containing one or two heteroatoms that are nitrogen, oxygen or sulfur.

### Claim 19 (depends on 13)

The method according to claim 13, wherein the anti-mycobacterial agent is an anti-tuberculosis agent.

### Claim 20 (depends on 14)

The combination according to claim 14, wherein the anti-mycobacterial agent is an anti-tuberculosis agent.

### Claim 21 (depends on 15)

The product according to claim 15, wherein the anti-mycobacterial agent is an anti-tuberculosis agent.
